{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:06:46Z","timestamp":1776388006273,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.atherosclerosis.2004.02.009","type":"journal-article","created":{"date-parts":[[2004,5,8]],"date-time":"2004-05-08T07:05:44Z","timestamp":1083999944000},"page":"275-285","source":"Crossref","is-referenced-by-count":8,"title":["Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration"],"prefix":"10.1016","volume":"174","author":[{"given":"Carme","family":"Trocho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Carles","family":"Escol\u00e0-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicent","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f2nia","family":"Ben\u0131\u0301tez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas M","family":"Mart\u0131\u0301n-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Rotllan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Osaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ord\u00f3\u00f1ez-Llanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Gonz\u00e1lez-Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0002-9149(99)00826-7","article-title":"Raising low levels of high-density lipoprotein cholesterol is an important target of therapy","volume":"85","author":"Boden","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0002-9149(00)01029-8","article-title":"Why not phenytoin?","volume":"86","author":"Lane","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bmj.291.6507.1481","article-title":"Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study","volume":"291","author":"Muuronen","year":"1985","journal-title":"Br Med J"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB4","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/01.ATV.15.12.2151","article-title":"A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol","volume":"15","author":"Miller","year":"1995","journal-title":"Arterioscler Thromb. Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/j.1552-4604.1995.tb04118.x","article-title":"Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol","volume":"35","author":"Goerdt","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB6","doi-asserted-by":"crossref","first-page":"d515","DOI":"10.2741\/Fazio","article-title":"Mouse models of hyperlipidemia and atherosclerosis","volume":"6","author":"Fazio","year":"2001","journal-title":"Front Biosci"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/bmme.1995.1069","article-title":"Induction of microsomal epoxide hydrolase activity in inbred mice by chronic phenytoin exposure","volume":"56","author":"Hartsfield","year":"1995","journal-title":"Biochem Mol Med"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB8","unstructured":"Committee on care and use of laboratory animals. Guide for the care and use of laboratory animals. Washington, DC: Institute of Laboratory Animal Resources, National Research Council; 1985."},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0022-2275(20)31685-0","article-title":"ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance","volume":"42","author":"Escol\u00e0-Gil","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0022-2275(20)33441-6","article-title":"Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia","volume":"41","author":"Escol\u00e0-Gil","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB12","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1074\/jbc.271.12.6720","article-title":"Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II","volume":"271","author":"Marzal-Casacuberta","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB14","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/bi961191e","article-title":"Cholesterol efflux, lecithin:cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I\/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport","volume":"36","author":"Castro","year":"1997","journal-title":"Biocheistry"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0026-0495(99)90097-5","article-title":"Free cholesterol deposition in the cornea of human apolipoprotein A-II transgenic mice with funtional lecithin:cholesterol acyltransferase deficiency","volume":"48","author":"Julve-Gil","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1194\/jlr.M200081-JLR200","article-title":"Mechanisms of HDL mice overexpressing human apoA-II","volume":"43","author":"Julve","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.CIR.0000086981.09834.E0","article-title":"Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2105-3-4","article-title":"Sources of variability and effect of experimental approach on expression profiling data interpretation","volume":"3","author":"Bakay","year":"2002","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.ATV.0000030201.29121.A3","article-title":"Quantitative trait loci and candidate genes regulating HDL cholesterol. A murine chromosome map","volume":"22","author":"Wang","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB20","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI118687","article-title":"Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice","volume":"97","author":"Beou","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0009-9236(95)90213-9","article-title":"Microsoal enzyme inducers raise high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia","volume":"57","author":"Franceschini","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/hh0302.104462","article-title":"Loss of SR-BI eression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice","volume":"90","author":"Braun","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB23","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4\u03b2-hydroxycholesterol in humans","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0021-9150(03)00133-3","article-title":"Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes","volume":"169","author":"Dutta","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1091\/mbc.5.2.183","article-title":"Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component","volume":"5","author":"Woods","year":"1994","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/abbi.1999.1607","article-title":"Syndecan 4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts","volume":"374","author":"Woods","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB27","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1242\/jcs.112.20.3421","article-title":"Control of morphology, cytoskeleton and migration by syndecan-4","volume":"112","author":"Longley","year":"1999","journal-title":"J Cell Sci"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1242\/jcs.113.2.315","article-title":"Syndemos, a protein that interacts with the cytoplasmic domain of syndecan-4, mediates cell spreading and cytoskeletal organization","volume":"113","author":"Baciu","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1242\/jcs.115.1.227","article-title":"Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes","volume":"115","author":"Kaneider","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB30","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1172\/JCI10559","article-title":"Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4","volume":"107","author":"Echtermeyer","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB31","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1073\/pnas.96.6.2805","article-title":"Syndecan-4 signals cooperatively with integrins in a rho-dependent manner in the assembly of focal adhesions and actin stress fibers","volume":"96","author":"Saoncella","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB32","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/01.CIR.102.23.2803","article-title":"Simvastatin improves disturbed endothelial barrier function","volume":"102","author":"van Amerogen","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1749-6632.2000.tb06561.x","article-title":"Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lisophosphatidic acid receptors and the rho\/rho kinase pathway. Inhibition by lovastatin","volume":"905","author":"Essler","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB34","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1074\/jbc.273.17.10530","article-title":"Molecular cloning, characterization, and promotor analysis of the mouse crp2\/SmLim gene. Preferential expression of its promoter in the vascular smooth muscle cells of transgenic mice","volume":"273","author":"Yet","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0092-8674(94)90368-9","article-title":"Defective T cell receptor signaling and CD8(+) thymic selection in humans lacking Zap-70 kinase","volume":"76","author":"Arpaia","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2004.02.009_BIB36","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI119821","article-title":"Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha","volume":"100","author":"Modur","year":"1997","journal-title":"J Clin Invest"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915004001315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915004001315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:00:00Z","timestamp":1623927600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915004001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0021915004001315"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.02.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}